MedRx Co., Ltd (TYO:4586)

Market Cap	5.28B +35.7%
Revenue (ttm)	128.00M -50.2%
Net Income	-937.00M
EPS	-17.44
Shares Out	59.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	855,500
Average Volume	1,517,730
Open	89.00
Previous Close	89.00
Day's Range	86.00 - 90.00
52-Week Range	58.00 - 225.00
Beta	0.67
RSI	41.09
Earnings Date	May 8, 2026

About MedRx

MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops transdermal medicines based on the ionic liquid transdermal system (ILTS) and the nano-sized colloid transdermal system (NCTS); and microneedle arrays/patch vaccines for the delivery of vaccines and APIs through the skin. Its products also include MRX-5LBT, which has NDA approval in the United States for neuropathic pain; MRX-4TZT, which is in a Phase II trial for spastic paral...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 21
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4586

Financial Performance

In 2025, MedRx's revenue was 128.00 million, a decrease of -50.19% compared to the previous year's 257.00 million. Losses were -937.00 million, 16.3% more than in 2024.